170 related articles for article (PubMed ID: 12493780)
1. Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunodulator murabutide.
Bahr GM
J Antimicrob Chemother; 2003 Jan; 51(1):5-8. PubMed ID: 12493780
[No Abstract] [Full Text] [Related]
2. Murabutide revisited: a review of its pleiotropic biological effects.
Jakopin Ž
Curr Med Chem; 2013; 20(16):2068-79. PubMed ID: 23531213
[TBL] [Abstract][Full Text] [Related]
3. Clinical and immunological effects of a 6 week immunotherapy cycle with murabutide in HIV-1 patients with unsuccessful long-term antiretroviral treatment.
Bahr GM; De La Tribonniere X; Darcissac E; Ajana F; Bocket L; Sissoko D; Yazdanpanah Y; Dewulf J; Amiel C; Mouton Y
J Antimicrob Chemother; 2003 Jun; 51(6):1377-88. PubMed ID: 12716777
[TBL] [Abstract][Full Text] [Related]
4. New kinds of treatment.
AIDS Treat News; 2001 Jan; (377):4-5. PubMed ID: 11862809
[No Abstract] [Full Text] [Related]
5. Immune boosters. Murabutide--debut of a new immune booster?
TreatmentUpdate; 2003; 15(4):3. PubMed ID: 17216851
[No Abstract] [Full Text] [Related]
6. [The immunostimulating activity of muramyl dipeptide and its derivatives].
Karsonova MI; Andronova TM; Pinegin BV; Khaitov RM
Zh Mikrobiol Epidemiol Immunobiol; 1999; (3):104-10. PubMed ID: 10852007
[No Abstract] [Full Text] [Related]
7. Chemical synthesis and adjuvant activity of N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP) analogs 1, 2.
Kamisango K; Saiki I; Tanio Y; Kobayashi S; Fukuda T; Sekikawa I; Azuma I; Yamamura Y
Chem Pharm Bull (Tokyo); 1981 Jun; 29(6):1644-54. PubMed ID: 7296716
[No Abstract] [Full Text] [Related]
8. [Theoretical problems of use of an immunomodulator likopid in clinical practice].
Andronova TM; Chumakova MM
Ter Arkh; 2002; 74(1):70-2. PubMed ID: 11878067
[No Abstract] [Full Text] [Related]
9. [Muramyl dipeptide derivatives in experimental and clinical use].
Kaliuzhin OV
Zh Mikrobiol Epidemiol Immunobiol; 1998; (1):104-8. PubMed ID: 9532704
[No Abstract] [Full Text] [Related]
10. Synthesis of immunoadjuvant conjugates with HIV-derived peptide inducing peptide-specific antibody.
Maruyama Y; Kurimura M; Achiwa K
Chem Pharm Bull (Tokyo); 1994 Aug; 42(8):1709-11. PubMed ID: 7954925
[No Abstract] [Full Text] [Related]
11. Synthetic immunostimulants derived from the bacterial cell wall.
Lederer E
J Med Chem; 1980 Aug; 23(8):819-25. PubMed ID: 6995612
[No Abstract] [Full Text] [Related]
12. A phase I study of a six-week cycle of immunotherapy with Murabutide in HIV-1 patients naive to antiretrovirals.
De La Tribonniere X; Mouton Y; Vidal V; Darcissac E; Sissoko D; Fontier C; Douadi Y; Dewulf Jl; Amiel C; Bahr GM
Med Sci Monit; 2003 Jun; 9(6):PI43-50. PubMed ID: 12824957
[TBL] [Abstract][Full Text] [Related]
13. [Natural immunostimulants].
Nikitin AV; Navashin SM
Antibiotiki; 1983 Sep; 28(9):702-16. PubMed ID: 6357066
[No Abstract] [Full Text] [Related]
14. Synthesis and immunoadjuvant activity of N-[2-O-(2-acetamido- 1,2,3,5-tetradeoxy-1,5-imino-D-glucitol-3-yl)-D-lactoyl]- L-alanyl-D-isoglutamine.
Ishida H; Kitagawa M; Kiso M; Hasegawa A; Azuma I
Carbohydr Res; 1990 Dec; 208():267-72. PubMed ID: 2085813
[No Abstract] [Full Text] [Related]
15. [Mechanism of action and clinical effectiveness of immunomodulator glucosaminylmuramyl dipeptide (licopide)].
Ivanov VT; Andronova TM; Nesmeianov VA; Pinegin BV; Ledger P; Bomford R; Khaitov RM
Klin Med (Mosk); 1997; 75(3):11-5. PubMed ID: 9229604
[No Abstract] [Full Text] [Related]
16. The synthetic immunomodulator murabutide controls human immunodeficiency virus type 1 replication at multiple levels in macrophages and dendritic cells.
Darcissac EC; Truong MJ; Dewulf J; Mouton Y; Capron A; Bahr GM
J Virol; 2000 Sep; 74(17):7794-802. PubMed ID: 10933686
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of immunologically active muramyl dipeptide derivatives containing a quinonyl moiety via aminoacyl intermediates.
Fukuda T; Kobayashi S; Yukimasa H; Imada I; Fujino M; Azuma I; Yamamura Y
Chem Pharm Bull (Tokyo); 1981 Aug; 29(8):2215-21. PubMed ID: 7318034
[No Abstract] [Full Text] [Related]
18. Syntex adjuvant formulation.
Allison AC; Byars NE
Res Immunol; 1992 Jun; 143(5):519-25. PubMed ID: 1439132
[No Abstract] [Full Text] [Related]
19. Clinical tolerance and immunologic effects after single or repeated administrations of the synthetic immunomodulator murabutide in HIV-1-infected patients.
Amiel C; De La Tribonnière X; Vidal V; Darcissac E; Mouton Y; Bahr GM
J Acquir Immune Defic Syndr; 2002 Jul; 30(3):294-305. PubMed ID: 12131566
[TBL] [Abstract][Full Text] [Related]
20. Development of the cytokine inducer romurtide: experimental studies and clinical application.
Azuma I
Trends Pharmacol Sci; 1992 Dec; 13(12):425-8. PubMed ID: 1293866
[No Abstract] [Full Text] [Related]
[Next] [New Search]
